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Abstract: Chronic obstructive pulmonary disease (COPD) is associated with smoking but other 
etiological factors contribute. Chlamydia pneumoniae is an obligate intracellular bacterium 
causing both acute and chronic respiratory tract infections. Studies have revealed an associa-
tion between chronic C. pneumoniae infection and COPD, asthma and lung cancer but there 
have been difﬁ  culties detecting C. pneumoniae in the bronchial tree. Cytospin slides prepared 
from bronchoalveolar lavage (BAL) ﬂ  uid from 14 patients with COPD, 10 healthy smokers (S) 
and 7 non smokers (NS) were analyzed with a ﬂ  uorescein isothiocyanate labeled monoclonal 
antibody to C. pneumoniae. Lung tissue from 24 patients with advanced emphysema who had 
undergone lung volume reduction surgery (LVRS) was examined with immunohistochemistry 
for C. pneumoniae. Archived serum samples for detection of speciﬁ  c C. pneumoniae antibod-
ies by microimmunoﬂ  uorescence were available for 30 of the BAL subjects and 11 of LVRS 
patients. C. pneumoniae elementary body like structures were found in 29% of cytospin speci-
mens from COPD patients, 14% of NS and 10% of HS. C. pneumoniae was detected in lung 
tissue in 8%. COPD patients had higher titres of IgG and IgA than NS and S. There was no 
association between occurrence of C. pneumoniae in BAL ﬂ  uid and antibody titres. In conclu-
sion, the assays used for detection of C. pneumoniae in lung tissue are feasible, and could be 
adapted in adequately powered studies to further conﬁ  rm an association between C. pneumoniae 
infection and COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) has a signiﬁ  cant impact on burden of 
illness, and WHO predict that by 2020 COPD will be the 5th most prevalent disease 
worldwide and the 3rd most common cause of death (Lopez et al 1998; Michaud et al 
2001). Tobacco smoking is the major cause of COPD. However, since non-smokers 
can develop COPD and lung function deterioration continues rapidly in some patients 
despite smoking cessation, other etiological factors than smoking seem to contribute 
to the development of the disease. It is likely that both genetic and acquired host 
factors as well as environmental exposures, either separately or in combination may 
contribute to the development of the disease.
Chlamydia pneumoniae, an obligate intracellular bacterium with a unique biphasic 
replicative cycle, is an established cause of acute and chronic upper and lower respira-
tory tract infections. During the replicative cycle, C. pneumoniae presents as infectious 
elementary bodies and metabolically active intracellular reticulate bodies. Release of 
pro-inﬂ  ammatory cytokines in response to a chronic C. pneumoniae infection could International Journal of COPD 2007:2(4) 644
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potentially amplify inﬂ  ammation and damage of the lungs 
caused by cigarette smoke. Several studies have demon-
strated persistent elevated titres of speciﬁ  c IgA antibodies 
to C. pneumoniae in patients with COPD (von Hertzen et al 
1996; von Hertzen et al 1997), and we recently reported 
that serology suggestive of chronic C. pneumoniae infec-
tion was an independent risk factor for the development of 
COPD (Brandén et al 2005). Further, macrophages in lung 
tissue from patients with COPD have been reported to stain 
positive for C. pneumoniae LPS (Rupp et al 2004), and C. 
pneumoniae has also been detected in lung tissue from sub-
jects with COPD (Wu et al 2000).
The two major components of airways obstruction in 
COPD are small airways disease and emphysema, which both 
to a large extent are irreversible and cause permanent reduced 
lung function. Samples from these peripheral compartments 
of the lung can be obtained by bronchoalveolar lavage (BAL), 
and the present study was conducted to evaluate the useful-
ness of BAL ﬂ  uid cytospin preparations for the detection 
of C. pneumoniae. Further, we examined lung tissue from 
patients with advanced emphysema undergoing lung volume 
reduction surgery (LVRS) in order to evaluate the association 
between C. pneumoniae and severe COPD.
Material and methods
Study population
The investigated subjects were recruited in two separate 
studies. Both were approved by the Ethics Committee, 
Karolinska University Hospital, and informed consent was 
given by all patients.
Study A
Study A was performed April 2000 to June 2004, and included 
31 subjects; 14 with stable clinical COPD without any exac-
erbations for the last 3 months, and as controls 10 healthy 
smokers and 7 non-smokers with normal chest radiographs 
(Table 1). They consist of a sub-group of subjects from a pre-
vious study (Lofdahl et al 2005) where cytospin preparations 
from BAL were available. All subjects underwent spirometry 
and bronchoscopy with BAL, and the cells were concentrated 
on glass slides using a cytospin procedure. Analysis of speciﬁ  c 
C. pneumoniae antibodies in serum taken prior to bronchos-
copy was performed in all subjects except one.
Study B
Study B included 24 patients (15 females and 9 males), 
who had undergone LVRS for severe emphysema between 
January 1995 and May 2001. Six patients were homozygote 
for α1-antitrypsin deﬁ  ciency (4 females and 2 males), 3 were 
heterozygote (1 female and 2 males) and the other 15 had 
normal enzyme levels. The mean age was 61.6 years (SD 7.7). 
All were ex-smokers except one homozygote female. Infor-
mation on the smoking habits was based on medical records, 
and the information was not sufﬁ  cient to enable calculations 
in three subjects. Mean smoking pack-years (PY; product of 
years smoking and the number of cigarettes smoked per day 
divided by 20) 27.5 (SD 17.2). Spirometries were performed 
in all, and mean forced expired volume in one second (FEV1) 
was 23.8 (SD 4.8) % predicted. Reversibility was tested in 
all except two, and demonstrated in mean 3.3 (SD 3.4) % 
predicted. C. pneumoniae serology was available for 11 of 
the patients. Samples were collected taken at time of surgery 
in 7 patients, and 2–7 years post surgery in 4 patients.
Lung function tests
Lung function was determined by the use of dynamic 
spirometers, in Study A Vitalograph Compact (Vitalo-
graph Ltd, Buckingham, UK) and in Study B Gould 2400 
(Gould Electronics, Netherlands). The procedures were 
performed in a standardized manner, and the results for 
forced vital capacity (FVC), vital capacity (VC) and forced 
expiratory volume in one second (FEV1) were expressed 
as percentage of predicted values (Quanjer 1983; Quanjer 
et al 1993). Reversibility of airways obstruction was tested 
by measuring FEV1 before and 10 min after inhalation of 
bronchodilators; in Study A one mg terbutaline (Bricanyl 
Turbuhaler; AstraZeneca) and in Study B nebulisation of 
5 mg salbutamol (Ventoline; GlaxoSmithKline) and 0.25 
mg ipratropium bromide (Atrovent; Boehringer Ingelheim), 
and was calculated as improvement of FEV1 in percentage 
of predicted FEV1.
Bronchoscopy and bronchoalveolar 
lavage (BAL)
Bronchoscopy was performed on an outpatient basis 
after overnight fasting. Following pre-medication with 
morphin-hyoscine i.m. 45 min prior to the investigation, 
the bronchoscope (Olympus F Type P30, Olympus Opti-
cal Co, Ltd, Tokyo, Japan) was inserted nasally after 
topical anesthesia with lignocaine (Xylocain; AstraZeneca, 
Södertälje, Sweden). BAL was performed by wedging the 
bronchoscope in a sub-segment of the middle lobe. In one 
of the COPD patients BAL was performed in one of the 
basal sub-segments of the right lower lobe due to difﬁ  cul-
ties in wedging the bronchoscope in the middle lobe. Five 
aliquots of 50 ml of sterile phosphate buffered saline (PBS) International Journal of COPD 2007:2(4) 645
Cytospin specimens for detection of Chlamydia pneumoniae
adjusted to 37 °C were instilled and gently suctioned back 
with a negative pressure of −40 to –50 mm Hg. Dwell time 
was kept to a minimum as recommended by the European 
Respiratory Society task force (Haslam et al 1999). The 
procedure was interrupted if the recovery after 150–200 ml 
of instilled ﬂ  uid was  35 ml or in case of persistent cough 
or hypoxia to  90% oxygen saturation despite appropri-
ate oxygen supplement. The BAL ﬂ  uid was collected in a 
silicone treated bottle kept on ice, which was immediately 
transported to the laboratory. The ﬂ  uid was ﬁ  ltered through 
a Dacron membrane (Millipore, Cork, Ireland) and centri-
fuged onto microscope slides at 400x g for 10 min at 4 °C, 
then frozen at –80 °C.
Lung volume reduction surgery
Surgery was performed by median sternotomy except for a 
few cases in which thoracotomy was done. The most dam-
aged areas were removed with an ambition to reduce the 
lung volume with 30%.
Detection of C. pneumoniae in study A
Detection of C. pneumoniae was performed by direct 
ﬂ  uorescence antibody technique (DFA) on cytospin prepa-
rations of BAL ﬂ  uid. The cytospin specimens on glass 
microscope slides were ﬁ  xed in cold acetone for 15 minutes 
and dried in air. Twenty-ﬁ  ve microliters of a monoclonal 
antibody directed against C. pneumoniae (ImagenTM Chla-
mydia pneumoniae, DAKO Ltd, Cambridgeshire, UK) was 
overlaid on each specimen, and slides were incubated at 
37 °C for 30 min in a moist chamber. Positive and negative 
control slides were included in all runs. Slides provided 
in the Imagen kit containing C. pneumoniae infected cells 
served as positive controls, and C. pneumoniae infected 
cells incubated with a ﬂ  uorescein isothiocyanate labeled 
adenovirus monoclonal antibody were used as negative 
controls. Washing with gentle agitation was done with 
PBS pH 7.5 for 5 minutes, after which the slides were 
dried in air, mounted, coverslipped and examined imme-
diately using an UV microscope (Olympus B × 40) at 500x 
magniﬁ  cation. The presence of bright apple-green ﬂ  uo-
rescing round bodies concomitant in size with elementary 
bodies were considered as possible positive ﬁ  ndings for 
C. pneumoniae.
Detection of C. pneumoniae in study B
Immunohistochemistry (IHC) for C. pneumoniae was per-
formed with the patient identity blinded. Formalin ﬁ  xed lung 
tissue was embedded in parafﬁ  n and cut at a thickness of 
4 μm. The sections were placed on glass slides and deparaf-
ﬁ  nized according to standard procedure including clearing 
with xylene × 2, and hydrated through a series of alcohols 
with decreasing concentrations. The sections were over-
laid with 0.5% pepsin (Sigma Chemical Co, St. Louis, Mo) 
to open up the cells and incubated for 15 minutes at 37 °C. 
After washing with PBS-Tween 20 (PBST) at pH 7.6 × 2 for 
5 minutes, peroxidase blocking reagent (DAKO Corporation, 
Carpinteria, CA) was overlaid, and the slides were incubated 
for 15 minutes at room temperature in a moist chamber. 
Washing was done twice for 5 minutes in PBST and universal 
blocking solution (Dako Diagnostics Canada Inc, Missis-
sauga, ON) was overlaid and incubated for 15 min at room 
temperature. The slides were gently drained and a 1:5 dilution 
of mouse monoclonal antibody to Chlamydia pneumoniae 
RR-402 (DakoCytomation Ltd, Ely, UK) in antibody diluting 
buffer (DAKO Diagnostics Canada Inc., Mississauga, ON) 
was added. Slides were incubated overnight at 4 °C and then 
washed twice with PBST. StreptABComplex/HRP Duet, 
Mouse/Rabbit (Dako A/S, Glostrup, Denmark) was used 
for the streptavidin/biotin reaction using a biotinylated goat 
antibody to mouse and rabbit immunoglobulin, streptavidin 
Table 1 Characteristics of the population, presence of C. pneumoniae in cytospin from bronchoalveolar lavage and antibody titres 
against C. pneumoniae in patients with COPD, healthy smokers and non-smokers (Study A)
   COPD  Smokers  Non-smokers
   N = 14  N = 10  N = 7
Females N  6  7  4
Age (Years)  Mean (SD)  56.5 (3.7)  54.0 (8.4)  57.7 (5.0)
Pack-years  Mean (SD)  37.1 (7.0)  40.6 (24.1)  0.0 (0.0)
FEV1 (% predicted)  Mean (SD)  54.4 (9.8)b  100.5 (11.2)  108.9 (9.0)
Reversibility (% predicted)  Mean (SD)  5.3 (4.6)  3.1 (2.3)  3.1 (2.8)
BAL recovery (%)  Mean (SD)  36.2 (15.7)b  57.2 (13.3)  65.1 (11.3)
C. pneumoniaea in cytospin from BAL  N (%)  4 (29)  1 (10)  1 (14)
aElementary body like structures.
bp   0.001 vs smokers and non-smokers.International Journal of COPD 2007:2(4) 646
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and a biotinylated horseradish peroxidase. Finally, DAKO 
AEC Substrate System (DAKO Corporation, Carpinteria, 
CA) was used for visualization of the red coloured Chlamydia 
antigen in the tissue sections.
Tissue sections previously obtained from patients with 
lung cancer and proven C. pneumoniae infection were used as 
positive controls. As negative controls an antibody to mouse 
IgG3 (NeoMarkers, Fremont, CA), the same class of antibody 
as the RR-402 monoclonal, was used in all runs.
Serology for C. pneumoniae
C. pneumoniae antibodies were analyzed by microimmu-
noﬂ  uorescence (MIF) at an accredited clinical microbiol-
ogy laboratory using a previously standardized procedure 
(Gnarpe, Naas et al 2000; Gnarpe, Sparr et al 2000). All sera 
were separated from erythrocytes upon arrival at the labora-
tory and frozen at –20 °C until tested. Sera were diluted 1:32 
with PBS at pH 7.4 and tested for IgG and IgA antibodies 
using 21-well antigen slides with elementary bodies of 
C. psittaci, C.trachomatis and C. pneumoniae in each test 
well (LabSystems Oy; Helsinki, Finland).
Sera found to be positive in a 1/64 screening dilution 
for IgG were re-diluted and tested in doubling dilutions to 
endpoint. All positive sera were retested and sera positive 
for IgA were absorbed with Gullsorb (Gull Laboratories 
Ltd, USA) to remove IgG before dilution, and then tested 
in doubling dilutions. Serum dilutions were incubated with 
antigens for 14–16 h at 4 °C at all testing occasions. This 
prolonged incubation at 4 °C increases the sensitivity of 
the test: a 1/32 dilution of serum incubated overnight is 
equivalent to a titer of 1/8–1/16 when incubated for 30–60 
min in a conventional MIF test. Slides were washed thor-
oughly in three changes of PBS solution (pH 7.4), then 
incubated with ﬂ  uorescein isothio-cyanate-conjugated rab-
bit antihuman IgG or IgA (Dakopatts; Glostrup, Denmark) 
at 37 °C for 30 min. Control sera with speciﬁ  ed high and 
low titres were used on each testing occasion, and tests 
were accepted only if the titres were within one dilution 
step of the predetermined mean titres for the respective 
quality control sera. An experienced microbiologist read 
all tests with an UV microscope (Zeiss; Jena, Germany) 
using a 40x oil immersion lens and a 10x ocular lens (total 
magniﬁ  cation, x400).
Statistical analysis
Statistical analyses were only performed in Study A. 
Comparisons between the groups were performed by analysis 
of variance, and in case of statistical signiﬁ  cance (p   0.05), 
post-hoc analysis was performed with the LSD test. Analyses 
of difference in serological titres were performed after 
logarithmic transformation, and negative observations were 




C. pneumoniae species (apple green elementary body like 
structures) were detected with DFA on cytospin slides 
from BAL ﬂ  uid in 29% of the COPD patients, 10% of the 
healthy smokers and 14% of the never-smokers (Table 1 and 
Figure 1). No inclusion bodies in the cells were observed 
on the cytospins. The speciﬁ  c IgG-antibody titres were sig-
niﬁ  cantly higher in the COPD patients than in the healthy 
smokers and non-smokers (Figure 2). The prevalence of 
speciﬁ  c IgG antibody titre  1/128 were 64% in the COPD 
patients, 30% in the smokers and 33% in the never-smokers. 
Corresponding ﬁ  gures for speciﬁ  c IgA-antibody titre  1/64 
were 29%, 10% and 17%. None of the differences between 
the groups was statistically significant. There was no 
correlation between high antibody titres and detection 
of the C. pneumoniae elementary bodies in the cytospin 
preparations.
Study B
No signs of inﬂ  ammation were observed in the majority 
of lung tissue samples from the subjects with advanced 
emphysema. C. pneumoniae was detected with IHC in 
lung tissue from 2 of 24 patients with advanced emphy-
sema, one female with α1-antitrypsin deficiency who 
had never smoked and one male ex-smoker with normal 
α1-antitrypsin level. Serology for C. pneumoniae antibod-
ies was not available for these two individuals. For those 
subjects where sera for antibody analyses were available, 
speciﬁ  c IgG-antibodies titres  1/128 were detected in 
55% and IgA titres  1/64 in 36% of the subjects. In those 
where sera were available at the time of surgery 57% had 
IgA titres  1/64.
Discussion
In this study we demonstrated that C. pneumoniae elemen-
tary body like structures could be detected in cytospin 
preparations of BAL fluid with a higher, although not 
statistically signiﬁ  cant, prevalence in subjects with COPD 
than in healthy smokers and non-smokers. Further, the 
speciﬁ  c IgG and IgA antibody titres were higher in subjects 
with COPD than in healthy smokers and non-smokers. We International Journal of COPD 2007:2(4) 647
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have also shown that C. pneumoniae could be detected in 
lung tissue from 2 of 24 subjects undergoing surgery for 
severe emphysema.
Sero-epidemiological studies have demonstrated that 
C. pneumoniae is a common and widespread pathogen with 
50% of adults in the general population having detectable 
IgG antibody titres (Grayston 1989). This was conﬁ  rmed 
in the present study, which demonstrated a high prevalence 
(71%) of IgG titres  1/64. Several studies have shown 
an association between chronic C. pneumoniae infection 
deﬁ  ned by serological criteria and COPD (von Hertzen et al 
1996; von Hertzen et al 1997; Smieja et al 2002; Brandén 
et al 2005; Kurashima et al 2005). This study conﬁ  rms such 
an association, since subjects with COPD had signiﬁ  cantly 
higher speciﬁ  c IgG titres than healthy individuals with a 
similar smoking history. The persistence of elevated titres of 
short-lived IgA has been proposed as a marker for chronic, 
recurrent or active carrier state (Saikku et al 1992). Chronic 
C. pneumoniae infection is thus strongly indicated in case of 
elevated speciﬁ  c IgA levels in paired serum samples taken 
with an extended interval. Since our study did not include 
repeated serological investigations, the results must be 
interpreted with caution, since a single elevated value can 
represent an acute infection. However, none of the subjects 
showed any signs of respiratory infection at the time of the 
investigation. In this study a larger proportion of subjects 
with COPD than healthy smokers and non-smokers had 
IgA titres  1/64, but the difference was not statistically 
signiﬁ  cant.
Although the association between serological signs 
of chronic C. pneumoniae infection and COPD is well 
established, knowledge about the host cells and tissues for 
the infection is limited. It has been reported that COPD 
patients are more likely to have C. pneumoniae DNA in 
peripheral blood mononuclear cells than patients undergo-
ing coronary angiography (Smieja et al 2002), and there are 
several publications demonstrating an association between 
C. pneumoniae and atherosclerosis (Saikku et al 1988; 
Muhlestein et al 1996; Campbell et al 1998). To strengthen 
a causal relationship with COPD, presence of the micro-
organism should ideally be demonstrated in lung tissue. 
C. pneumoniae can be detected by a number of methods such 
as immunohistochemistry, PCR (polymerase chain reaction)
 on lung tissue and culture of fresh tissues. We only analyzed 
Figure 1 Round elementary body like structure detected with DFA on cytospin slide from BAL ﬂ  uid. The apple green color is not visible on this photo.International Journal of COPD 2007:2(4) 648
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the specimens with immunohistochemistry, and due to lack 
of good specimens we could unfortunately not verify the 
ﬁ  ndings with other methods.
C. pneumoniae has previously been identified in 
emphysematous tissue (Wu et al 2000; Rupp et al 2004; 
Theegarten et al 2004), and we could conﬁ  rm the presence 
of C. pneumoniae in lung tissue from two out of 24 subjects 
who had undergone lung volume reduction surgery due to 
severe emphysema. The detection rate corresponds with the 
ﬁ  ndings in two of the previously reported studies (Rupp 
et al 2004; Theegarten et al 2004), but was considerably 
lower than in another study (Wu et al 2000). However, in 
Wu’s study archival tissue from subjects who had under-
gone lobectomy for bronchial carcinoma was analyzed, and 
this could have inﬂ  uenced the results. Several studies have 
reported an association between chronic C. pneumoniae 
infection and lung cancer (Laurila et al 1997; Jackson et al 
2000; Koyi et al 2001; Kocazeybek 2003), and the organism 
has been detected in macrophages close to the lung cancer 
using the same staining techniques as in the present study 
(Koyi et al 2001).
The low rate of detection of C. pneumoniae in emphy-
sematous tissue in this and other studies may be explained 
by the patchy localization of the infection (Kuo 2000), 
and that the investigated tissue samples only represent 
a very limited part of the lungs. BAL covers a larger 
compartment including small airways, which are affected 
in COPD. The retained BAL ﬂ  uid can either be used for 
cultivation or for identiﬁ  cation of micro-organisms with 
immunological methods. Cultivation of C. pneumoniae 
is difﬁ  cult, and tissue specimens should undergo primary 
isolation procedures plus 4–6 additional passages (Dowell 
et al 2001). Since this was a retrospective study, freshly 
procured samples were not available for cultivation, and 
we used immunological techniques with monoclonal 
antibodies for detection of the micro-organism on ﬁ  xed 
cytospin preparations.
C. pneumoniae has previously been detected by DFA 
on buffy coat cell pellets from BAL of children with 
asthma and other lung diseases (Webley et al 2005), but to 
our knowledge, no previous study has aimed to detect C. 
pneumoniae from BAL ﬂ  uid cytospin preparations. Using 
DFA, we found elementary body like structures on cytospin 
slides in four subjects with COPD, in one healthy smoker 
and in one non-smoker. As the specimens were archival 
we had no possibility to conﬁ  rm the identity of these struc-
tures. It is known that some bacteria, like Staphylococcus 
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Figure 2 Presence of C.pneumoniae in cytospin from bronchoalveolar lavage and antibody titres against C. pneumoniae in patients with COPD (C), healthy smokers (S) and 
non-smokers (NS) (Study A). Filled ﬁ  gures represent presence and unﬁ  lled absence of C.pneumoniae.International Journal of COPD 2007:2(4) 649
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FITC-labeled antibody and cause false positive results, 
but this bacterium should not be present in the lung and 
the organisms are usually larger than the elementary body 
of C. pneumoniae. Further analysis with other techniques 
such as PCR are needed to conﬁ  rm the identiﬁ  cation of C. 
pneumoniae. However, our ﬁ  nding of elementary body like 
structures in cytospin preparations from BAL is interesting, 
and if conﬁ  rmed, could add information on an association 
between C. pneumoniae infection and COPD. Appropri-
ately designed and powered studies are needed to conﬁ  rm 
this ﬁ  nding.
A disadvantage of studying BAL in COPD is that the 
recovery of ﬂ  uid often is low (Linden et al 1993; Soler 
et al 1999), which also was seen in this study. This might 
inﬂ  uence the reliability of the sampling, since in case of 
low recovery the BAL ﬂ  uid may not ideally represent the 
distal bronchial tree but rather reﬂ  ect conditions in large 
airways.
Long term studies using C. pneumoniae serology 
are needed to reveal whether chronic infections initiate 
the development of COPD or occur as a consequence of 
reduced immune response in a compromised lung. To further 
strengthen a causal relationship between chronic infections 
and COPD, the bacteria should ideally be identiﬁ  ed in the 
lungs. Although this study was not powered to conﬁ  rm an 
association between C. pneumoniae infection and COPD, 
we have demonstrated that the assays used for detection 
of the organism in cytospin from BAL and resected lung 
tissue are feasible, and thus could be adapted in adequately 
sized studies.
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